ANTX
AN2 Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.23 EPS
Last earnings +6.5% on 2026-05-11
$5.20
▲ +1.17%$5.20▲ +381.48%
over 1Y
L $1.03EODHDH $5.46
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+1.2%
1W+1.2%
1M+12.3%
3M+42.1%
YTD+368.5%
1Y+381.5%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity 0.17x).
Return on equity -66.3% · latest
AN2 Therapeutics, Inc. shows limited reported revenue, and -66.3% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$21.6M | -$42.3M | -$69.6M | -$56.8M | -$38.1M |
| Net income | -$21.5M | -$41.0M | -$64.7M | -$51.3M | -$35.2M |
| Diluted EPS | -$10.64 | -$2.79 | -$2.74 | -$1.72 | -$1.16 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$167M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-18.8%
FCF yield—
Quality & risk
ROIC (est.)-56.7%
Free cash flow—
Total debt—
Net cash$19.9M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+19.4%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-032026-06-09open ↗8-KPeriod ending 2026-06-042026-06-04open ↗4Period ending 2026-05-292026-06-02open ↗SCHEDULE 13G/AFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-11open ↗8-KPeriod ending 2026-05-112026-05-11open ↗ARSPeriod ending 2025-12-312026-04-22open ↗DEFA14AFiling2026-04-22open ↗DEF 14APeriod ending 2026-04-222026-04-22open ↗EFFECTFiling2026-04-20open ↗424B3Filing2026-04-20open ↗424B5Filing2026-04-20open ↗
Frequently asked
- Is AN2 Therapeutics, Inc. (ANTX) a buy?
- ANTX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.17x).
- What is AN2 Therapeutics, Inc.'s quality score?
- ANTX scores 59.87179487179487/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001880438, latest 10-Q filed 2026-05-11) · EODHD · as of 6/26/2026, 7:17:43 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.